Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions

 
• By Bridget Silverman
  
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers